For clinical studies, co-administration of Huaier or HQH as adjuvant therapy has been reported to reduce CD8+ T lymphocytes in advanced breast cancer patients (73), pediatric patients with primary nephrotic syndrome (74) and severe Mycoplasma pneumonia (13). The gene discussed is CD8A; the disease is breast cancer.